Source:http://linkedlifedata.com/resource/pubmed/id/10667100
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2000-3-16
|
pubmed:abstractText |
This study was carried out in the tuberculosis laboratory of the Institut National d'Hygiène in Rabat, Morocco, in 1997. The aim was to determine the percentages of drug-resistant strains by using 150 antibiograms. Six antimycobacterial medications were used as tuberculosis treatment: isoniazid (INH), streptomycin (STM), rifampicin (RIF), ethambutol (EMB), kanamycin (KAN) and p-amino-salicylic acid (PAS). The cultures were plated onto a simple agar (Lowenstein-Jensen) plate containing different concentrations of drugs. This test demonstrated the presence of major antimycobacterial (INH, RIF, STM)-resistant strains of Mycobacterium tuberculosis in the following percentages respectively: 34.6 per cent, 33.1 per cent and 26.1 per cent and 80 per cent, 70 per cent and 40 per cent in the case of atypical mycobacteria. The association of INH/RIF showed the highest percentage (27.6 per cent) for Mycobacterium tuberculosis and 70 per cent for atypical strains, whereas, when we associate INH/RIF/STM, the resistance rate becomes 17.69 per cent for Mycobacterium tuberculosis and 25 per cent for atypical mycobacteria. The resistance in question was a secondary or acquired resistance because the tested strains were isolated from patients who had not responded to standard tuberculosis treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aminosalicylic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Antitubercular Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Ethambutol,
http://linkedlifedata.com/resource/pubmed/chemical/Isoniazid,
http://linkedlifedata.com/resource/pubmed/chemical/Kanamycin,
http://linkedlifedata.com/resource/pubmed/chemical/Rifampin,
http://linkedlifedata.com/resource/pubmed/chemical/Streptomycin
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0040-5957
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
54
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
623-5
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10667100-Aminosalicylic Acid,
pubmed-meshheading:10667100-Antitubercular Agents,
pubmed-meshheading:10667100-Drug Resistance, Microbial,
pubmed-meshheading:10667100-Drug Resistance, Multiple,
pubmed-meshheading:10667100-Ethambutol,
pubmed-meshheading:10667100-Humans,
pubmed-meshheading:10667100-Isoniazid,
pubmed-meshheading:10667100-Kanamycin,
pubmed-meshheading:10667100-Microbial Sensitivity Tests,
pubmed-meshheading:10667100-Morocco,
pubmed-meshheading:10667100-Mycobacterium Infections, Nontuberculous,
pubmed-meshheading:10667100-Mycobacterium tuberculosis,
pubmed-meshheading:10667100-Nontuberculous Mycobacteria,
pubmed-meshheading:10667100-Rifampin,
pubmed-meshheading:10667100-Streptomycin,
pubmed-meshheading:10667100-Tuberculosis, Multidrug-Resistant
|
pubmed:articleTitle |
Mycobacterium resistance to antimycobacterial reagent.
|
pubmed:affiliation |
Institut National d'Hygiène, Rabat Agdal, Morocco.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|